Conceptual, Regulatory and Strategic Imperatives in the Early Days of EEG-Based Biomarker Validation for Neurodevelopmental Disabilities

Joshua B. Ewen, John A. Sweeney, William Z. Potter

Research output: Contribution to journalReview article

Abstract

Biological treatment development for syndromal neuropsychiatric conditions such as autism has seen slow progress for decades. Speeding drug discovery may result from the judicious development and application of biomarker measures of brain function to select patients for clinical trials, to confirm target engagement and to optimize drug dose. For neurodevelopmental disorders, electrophysiology (EEG) offers considerable promise because of its ability to monitor brain activity with high temporal resolution and its more ready application for pediatric populations relative to MRI. Here, we discuss conceptual/definitional issues related to biomarker development, discuss practical implementation issues, and suggest preliminary guidelines for validating EEG approaches as biomarkers with a context of use in neurodevelopmental disorder drug development.

Original languageEnglish (US)
Article number45
JournalFrontiers in Integrative Neuroscience
Volume13
DOIs
StatePublished - Aug 21 2019
Externally publishedYes

Fingerprint

Electrophysiology
Biomarkers
Aptitude
Brain
Drug Discovery
Autistic Disorder
Pharmaceutical Preparations
Clinical Trials
Guidelines
Pediatrics
Population
Neurodevelopmental Disorders
Therapeutics

Keywords

  • autism
  • biomarker
  • EEG
  • neuropsychiatry
  • validation

ASJC Scopus subject areas

  • Sensory Systems
  • Cognitive Neuroscience
  • Cellular and Molecular Neuroscience

Cite this

Conceptual, Regulatory and Strategic Imperatives in the Early Days of EEG-Based Biomarker Validation for Neurodevelopmental Disabilities. / Ewen, Joshua B.; Sweeney, John A.; Potter, William Z.

In: Frontiers in Integrative Neuroscience, Vol. 13, 45, 21.08.2019.

Research output: Contribution to journalReview article

@article{1e8ad8400a884b77bc92f6572536a4b3,
title = "Conceptual, Regulatory and Strategic Imperatives in the Early Days of EEG-Based Biomarker Validation for Neurodevelopmental Disabilities",
abstract = "Biological treatment development for syndromal neuropsychiatric conditions such as autism has seen slow progress for decades. Speeding drug discovery may result from the judicious development and application of biomarker measures of brain function to select patients for clinical trials, to confirm target engagement and to optimize drug dose. For neurodevelopmental disorders, electrophysiology (EEG) offers considerable promise because of its ability to monitor brain activity with high temporal resolution and its more ready application for pediatric populations relative to MRI. Here, we discuss conceptual/definitional issues related to biomarker development, discuss practical implementation issues, and suggest preliminary guidelines for validating EEG approaches as biomarkers with a context of use in neurodevelopmental disorder drug development.",
keywords = "autism, biomarker, EEG, neuropsychiatry, validation",
author = "Ewen, {Joshua B.} and Sweeney, {John A.} and Potter, {William Z.}",
year = "2019",
month = "8",
day = "21",
doi = "10.3389/fnint.2019.00045",
language = "English (US)",
volume = "13",
journal = "Frontiers in Integrative Neuroscience",
issn = "1662-5145",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Conceptual, Regulatory and Strategic Imperatives in the Early Days of EEG-Based Biomarker Validation for Neurodevelopmental Disabilities

AU - Ewen, Joshua B.

AU - Sweeney, John A.

AU - Potter, William Z.

PY - 2019/8/21

Y1 - 2019/8/21

N2 - Biological treatment development for syndromal neuropsychiatric conditions such as autism has seen slow progress for decades. Speeding drug discovery may result from the judicious development and application of biomarker measures of brain function to select patients for clinical trials, to confirm target engagement and to optimize drug dose. For neurodevelopmental disorders, electrophysiology (EEG) offers considerable promise because of its ability to monitor brain activity with high temporal resolution and its more ready application for pediatric populations relative to MRI. Here, we discuss conceptual/definitional issues related to biomarker development, discuss practical implementation issues, and suggest preliminary guidelines for validating EEG approaches as biomarkers with a context of use in neurodevelopmental disorder drug development.

AB - Biological treatment development for syndromal neuropsychiatric conditions such as autism has seen slow progress for decades. Speeding drug discovery may result from the judicious development and application of biomarker measures of brain function to select patients for clinical trials, to confirm target engagement and to optimize drug dose. For neurodevelopmental disorders, electrophysiology (EEG) offers considerable promise because of its ability to monitor brain activity with high temporal resolution and its more ready application for pediatric populations relative to MRI. Here, we discuss conceptual/definitional issues related to biomarker development, discuss practical implementation issues, and suggest preliminary guidelines for validating EEG approaches as biomarkers with a context of use in neurodevelopmental disorder drug development.

KW - autism

KW - biomarker

KW - EEG

KW - neuropsychiatry

KW - validation

UR - http://www.scopus.com/inward/record.url?scp=85072730584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072730584&partnerID=8YFLogxK

U2 - 10.3389/fnint.2019.00045

DO - 10.3389/fnint.2019.00045

M3 - Review article

C2 - 31496945

AN - SCOPUS:85072730584

VL - 13

JO - Frontiers in Integrative Neuroscience

JF - Frontiers in Integrative Neuroscience

SN - 1662-5145

M1 - 45

ER -